| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (1993) 31, 463-471
© 1993 The British Society for Antimicrobial Chemotherapy
review-article |
Resistance of yeasts to azole-derivative antifungals
Department of Bacteriology and Mycology, Janssen Research Foundation B-2340 Beerse, Belgium
Received 20 May 1992; accepted 28 July 1992
There are relatively few antifungal agents available for the treatment of systemic mycoses. The incidence of these infections, particularly among the immunocompromised, has increased significantly in recent years. Amphotericin B, flucytosine and the azole-derivatives—fluconazole, itraconazole and ketoconazole—are the only drugs of value in the treatment of systemic yeast infections currently available. To date resistance among individual yeast species or strains has only been a serious problem with flucytosine. However, resistance among Candida spp. to orally administered azole-derivatives has been observed. The frequency with which resistance has been described in clinical practice among yeasts differs considerably between the three azole antifungal agents. Fluconazole has been implicated in emergent resistance more frequently than ketoconazole, and ketoconazole more often than itraconazole. It must be a matter for concern that, by analogy with the known emergence of antibiotic-resistance among bacteria, that the widespread use of a drug inactive against a particular species may lead to an increased incidence of such infections. An international epidemiological survey is required to establish the extent and degree of resistance to the azole antifungals.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Ray, R. Goswami, U. Banerjee, V. Dadhwal, D. Goswami, P. Mandal, V. Sreenivas, and N. Kochupillai Prevalence of Candida glabrata and Its Response to Boric Acid Vaginal Suppositories in Comparison With Oral Fluconazole in Patients With Diabetes and Vulvovaginal Candidiasis Diabetes Care, February 1, 2007; 30(2): 312 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kaufman and K. D. Fairchild Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants Clin. Microbiol. Rev., July 1, 2004; 17(3): 638 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Jurevic, M. Bai, R. B. Chadwick, T. C. White, and B. A. Dale Single-Nucleotide Polymorphisms (SNPs) in Human {beta}-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type I Diabetics and Nondiabetic Controls J. Clin. Microbiol., January 1, 2003; 41(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barchiesi, M. Maracci, B. Radi, D. Arzeni, I. Baldassarri, A. Giacometti, and G. Scalise Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy J. Antimicrob. Chemother., December 1, 2002; 50(6): 999 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Natsch, M. H. M. Steeghs, Y. A. Hekster, J. F. G. M. Meis, J. W. M. van der Meer, and B. J. Kullberg Use of fluconazole in daily practice: still room for improvement J. Antimicrob. Chemother., August 1, 2001; 48(2): 303 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boogaerts, J. Maertens, A. van Hoof, R. de Bock, G. Fillet, M. Peetermans, D. Selleslag, B. Vandercam, K. Vandewoude, P. Zachee, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients J. Antimicrob. Chemother., July 1, 2001; 48(1): 97 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-M. C. Muller, M. Weig, J. Peter, and T. J. Walsh Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis J. Antimicrob. Chemother., August 1, 2000; 46(2): 338 - 341. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Younsi, E. Ramanandraibe, R. Bonaly, M. Donner, and J. Coulon Amphotericin B Resistance and Membrane Fluidity in Kluyveromyces lactis Strains Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1911 - 1916. [Abstract] [Full Text]
|
|
|
|
|
|
F. Barchiesi, D. Calabrese, D. Sanglard, L. Falconi Di Francesco, F. Caselli, D. Giannini, A. Giacometti, S. Gavaudan, and G. Scalise Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750 Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1578 - 1584. [Abstract] [Full Text]
|
|
|
|
|
|
D. R. Soll The Ins and Outs of DNA Fingerprinting the Infectious Fungi Clin. Microbiol. Rev., April 1, 2000; 13(2): 332 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Cross, J. Bagg, and T. C. Aitchison Efficacy of the Cyclodextrin Liquid Preparation of Itraconazole in Treatment of Denture Stomatitis: Comparison with Itraconazole Capsules Antimicrob. Agents Chemother., February 1, 2000; 44(2): 425 - 427. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Cowen, C. Sirjusingh, R. C. Summerbell, S. Walmsley, S. Richardson, L. M. Kohn, and J. B. Anderson Multilocus Genotypes and DNA Fingerprints Do Not Predict Variation in Azole Resistance among Clinical Isolates of Candida albicans Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2930 - 2938. [Abstract] [Full Text]
|
|
|
|
|
|
P. L. Fidel Jr., J. A. Vazquez, and J. D. Sobel Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans Clin. Microbiol. Rev., January 1, 1999; 12(1): 80 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. McElhaney-Feser, R. E. Raulli, and R. L. Cihlar Synergy of Nitric Oxide and Azoles against Candida Species In Vitro Antimicrob. Agents Chemother., September 1, 1998; 42(9): 2342 - 2346. [Abstract] [Full Text]
|
|
|
|
|
|
B. M. Mannarelli and C. P. Kurtzman Rapid Identification of Candida albicans and Other Human Pathogenic Yeasts by Using Short Oligonucleotides in a PCR J. Clin. Microbiol., June 1, 1998; 36(6): 1634 - 1641. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. White, K. A. Marr, and R. A. Bowden Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 1998; 11(2): 382 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Como and W. E. Dismukes Oral Azole Drugs as Systemic Antifungal Therapy N. Engl. J. Med., January 27, 1994; 330(4): 263 - 272. [Full Text]
|
|